Qiagen (QGEN) Receives Daily News Impact Rating of 1.50

Media headlines about Qiagen (NYSE:QGEN) have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 6,000 blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Qiagen earned a coverage optimism score of 1.50 on their scale. InfoTrie also gave press coverage about the company an news buzz score of 7 out of 10, indicating that recent press coverage is likely to have an effect on the stock’s share price in the immediate future.

Here are some of the media headlines that may have impacted Qiagen’s score:

Several research firms have commented on QGEN. Barclays reissued a “buy” rating and set a $43.00 price objective on shares of Qiagen in a report on Thursday, September 6th. Commerzbank reissued a “buy” rating on shares of Qiagen in a report on Monday, September 17th. Morgan Stanley increased their price objective on shares of Qiagen from $39.00 to $41.00 and gave the company an “overweight” rating in a report on Wednesday, October 31st. Finally, Deutsche Bank increased their price objective on shares of Qiagen from $43.00 to $44.00 and gave the company a “buy” rating in a report on Friday, October 5th. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $41.00.

Shares of NYSE:QGEN opened at $35.44 on Friday. The company has a quick ratio of 1.25, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Qiagen has a 12 month low of $30.78 and a 12 month high of $39.45. The stock has a market capitalization of $8.09 billion, a P/E ratio of 27.91, a price-to-earnings-growth ratio of 2.29 and a beta of 1.02.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Monday, October 29th. The company reported $0.35 EPS for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.02. Qiagen had a net margin of 6.00% and a return on equity of 12.52%. The firm had revenue of $377.91 million during the quarter, compared to the consensus estimate of $382.16 million. On average, sell-side analysts forecast that Qiagen will post 1.33 earnings per share for the current year.

WARNING: This news story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/12/07/qiagen-qgen-receives-daily-news-impact-rating-of-1-50.html.

Qiagen Company Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Featured Article: How much can an individual set aside as a catch-up contribution?

Insider Buying and Selling by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply